Delivery Order SPE2DB24D9222-SPE2DB25FAZKC
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 28, 2025, valued at $4,169.59 for the supply of Xtandi 40 mg tablets (120 count) to the Defense Logistics Agency (DLA). This firm fixed-price delivery order, which must be completed by July 29, 2025, carries no set-aside designation. The award leverages DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on August 18, 2025, for the supply of Xtandi 80 mg tablets in quantities of 60. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 19, 2025. This award was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. This award was issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency on July 28, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, represents a specific product requisition under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a firm fixed-price delivery order from the Defense Logistics Agency (DLA) valued at $4,169.59 for 60 tablets of Xtandi 80 mg. The award, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a standard pharmaceutical supply delivery to support Department of Defense healthcare operations. This delivery order was issued without a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,017.54 on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The award was issued under a firm fixed-price contract type with no set-aside designation, reflecting the company's competitive standing in federal procurement markets. The funding agency is the Defense Logistics Agency's Medical Supply Chain division, and...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 30, 2025, for 120 tablets of Xtandi 40 mg with a ceiling value of $8,339.18. This firm fixed-price delivery order, which has an ultimate completion date of July 31, 2025, was issued without a set-aside designation and is funded through the Defense Logistics Agency's Medical Supply Chain. The award represents a single delivery order under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, with an ultimate completion date of July 23, 2025, represents a discrete purchase under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 on August 12, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The Defense Logistics Agency issued this firm fixed-price delivery order under its larger Indefinite Delivery Contract with DMS Pharmaceutical Group, which is valued at $500 million and remains active through November 2026. The contract carries no set-aside...
- SPE2DB24D9222Indefinite Delivery Contract
- SPE2DB24D9222-SPE2DB25FAZKCDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency (DLA) on August 25, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). The award carries a firm fixed-price structure with an ultimate completion date of August 26, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis in the federal procurement market. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which is valued at $499,999,999 and remains valid through November 2026. The IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting the medical supply needs of military health facilities worldwide. Xtandi, an oncology treatment, represents one of many specialized pharmaceutical products within the company's extensive portfolio of branded and generic prescription drugs, biologics, and medical consumables delivered to Department of Defense healthcare sites.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 8/25/25 |